Recent News

December 31, 2018

Valiated reporting guidelines for adherence research EMERGE

Medication non-adherence is a global health problem of striking magnitude with major economic consequences. After four decades of research, methodological challenges in conducting and reporting adherence research remain and little is known about how to successfully translate effective adherence improving interventions into clinical practice. Under the auspices of the European Society for Patient Adherence (ESPACOMP,; ), an international panel of experts recently established an innovative and internationally validated set of reporting guidelines to enhance the quality of adherence research  go to link reporting. The  go here international expert Delphi panel resulted in the development of ESPACOMP Medication Adherence Reporting Guideline (EMERGE): [

Consistent with a standard definition of medication adherence [], EMERGE complements existing reporting guidelines  follow link (e.g. STROBE, CONSORT, STaRI) and provides researchers, authors and journal editors with guidance on best practices for reporting observational and interventional studies relating to medication adherence. By using EMERGE, our objective is to improve the transparency and detail of reporting to enhance the field of medication adherence by making it possible to synthesize findings across study, with the ultimate goal of moving effective adherence support programs into healthcare policy and practice.

September 19, 2018

Meet the Rebate, the New Villain of High Drug Prices

A growing chorus, including the Trump administration, is calling for a rethinking of after-the-fact drug discounts that some say contribute to rising prices. An increasingly popular culprit in the debate over high drug prices is the pharmaceutical rebate, the after-the-fact discounts that form the heart of the nation’s arcane — many would say broken — market for prescription drugs. Click here to read more

September 19, 2018

Addressing Out-Of-Pocket Specialty Drug Costs In Medicare Part D: The Good, The Bad, The Ugly, And The Ignored

The cost of prescription drugs in the United States has been a popular topic of debate in recent years, particularly when it comes to specialty drugs with very high price tags. High-profile proposals and reports—including this year’s President’s Budget; the National Academies of Science, Engineering, and Medicine’s report on making medicines affordable; the Medicare Payment Advisory Commission (MedPAC) annual report to Congress; and the recent Department of Health and Human Services (HHS) Blueprint to Lower Drug Prices and Out-of-Pocket Costs—have made a variety of recommendations, leading to a flurry of reactions from all segments of the health care industry. Click here to read more